Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
NCT05769010Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Henan Cancer Hospital. Started Mar 2023; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05769010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769010.